Tag: GlobeNewswire

LAFAYETTE, Ind., Oct. 05, 2026 (GLOBE NEWSWIRE) — Wabash (NYSE: WNC) today announced that it will webcast its quarterly earnings conference call to review and discuss its financial results for the third quarter of 2026 on Thursday, October 29, 2026, beginning at 12:00 p.m. ET.

The call and an accompanying slide presentation will be accessible on the “Investors” section of Wabash’s website, www.onewabash.com, under “Events & Presentations.” The conference call will be accessible at the following link: https://events.q4inc.com/attendee/756116794 replay of the call will be available shortly after the conclusion of the presentation. Access to the replay will be available on the “Investors” section of Wabash’s website under “Events & Presentations.”

Wabash’s earnings press release, earnings slides and any other related presentation materials will be posted to the “Investors” section of Wabash’s website by 7:00 a.m. ET on the date of the earnings call and will remain available following the call.

Wabash: Changing How the World Reaches You 
Wabash (NYSE: WNC) combines physical and digital technologies to deliver innovative, end-to-end solutions that optimize supply chains across transportation, logistics and infrastructure markets. Headquartered in Lafayette, Indiana, Wabash designs, manufactures, and services an extensive range of products supporting first-to-final mile operations, including dry and refrigerated trailers and truck bodies, platform trailers, tank trailers, structural composites and more. In addition, through the Wabash Marketplace and Wabash Parts, customers gain access to a nationwide parts and service network, Trailers as a Service (TaaS)℠, and advanced tools designed to streamline operations and drive growth. By enabling businesses to thrive today and prepare for tomorrow, Wabash is Changing How the World Reaches You^®. Learn more at onewabash.com.

Media Contact:
Heidi Murphy
Heidi.murphy@padillaco.com

Investor Relations:
John Cummings
Sr. Director, FP&A & IR
(765) 262-2898
john.cummings@onewabash.com

Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options

ZUG, Switzerland, Oct. 05, 2026 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS) a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that insights from a Pharvaris-funded analysis of the multinational Adelphi Real World HAE Disease Specific Programme™ (DSP) dataset evaluating how HAE is managed in clinical practice have been published in Advances in Therapy.

The analysis evaluated real-world patterns of HAE disease management including frequency, severity, and characteristics of HAE attacks; use of long-term prophylaxis (LTP) and on-demand treatment (ODT); patient and physician decision-making around treating or not treating attacks; treatment adherence and reasons for suboptimal adherence; and patient and physician perspectives on treatment satisfaction and unmet needs.

“By incorporating both physician-reported clinical data and patient-reported experiences, this analysis provides a comprehensive view of how hereditary angioedema is managed in routine clinical practice,” said Peng Lu, M.D., Ph.D., President of Pharvaris. “Early diagnosis and effective treatment remain critical, yet this real-world analysis highlights remaining gaps between guideline-recommended care and the actual experience of people with HAE. Addressing these gaps may help improve treatment outcomes, enhance patient satisfaction, and optimize overall disease management. These findings highlight the importance of understanding how treatment decisions are made in real-world settings and the barriers that may still limit alignment with clinical guidelines. At Pharvaris, we are committed to supporting the HAE community by leveraging insights to inform decisions and to identify solutions that may further inform medical care and address the practical and clinical needs of patients and physicians in everyday practice.”

Study Insights
The analysis identified gaps that currently persist between guideline-recommended care and real-world practice. Patient satisfaction with treatment and the decision to change treatment were mostly driven by ease of portability, route of administration, perceived efficacy, and the odds of experiencing adverse events. In addition, treatment burden—particularly related to route of administration, convenience, and integration into daily life—continues to impact patient behavior and satisfaction.

With regards to on-demand treatment of attacks, a substantial proportion of patients do not treat all HAE attacks, most commonly because attacks are perceived as not severe enough to use treatments patients perceive being associated with increased burden. Other reasons included the lack of availability of therapy and pain associated with injectable treatments. With regards to LTP treatment satisfaction, daily oral treatment was preferred over biweekly or monthly injections. These findings highlight ongoing unmet needs and suggest that real-world factors, including patient preferences and treatment usability, play a critical role in treatment outcomes.

Study Details
The analysis used data from the Adelphi Real World HAE DSP, a cross-sectional, retrospective survey conducted between January 2023 and January 2024 across the United States, Europe, and Japan. The study included 225 physicians, who completed record-based assessments for 1,131 patients with HAE, as well as 279 patients who provided direct, self-reported insights through questionnaires. This dual approach enabled comparison of physician-reported clinical data with patient-reported experiences, offering a comprehensive view of real-world HAE management. The survey captured both clinical characteristics and patient perspectives, including treatment behaviors and quality-of-life impact. Although the HAE treatment landscape has evolved between the time of the survey and present, the findings from the study are still considered actual.

The full publication can be found here: https://link.springer.com/article/10.1007/s12325-026-03790-2

About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. For more information, visit https://pharvaris.com/.

Forward-Looking Statements
This press release contains certain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements relating to our future plans, studies and trials, and any statements containing the words “believe,” “anticipate,” “expect,” “estimate,” “may,” “could,” “should,” “would,” “will” and similar expressions. These forward-looking statements are based on management’s current expectations, are neither promises nor guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause Pharvaris’ actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements. Such risks include but are not limited to the following: uncertainty in the outcome of our interactions with regulatory authorities, including the FDA; the expected timing, progress, or success of our clinical development programs, especially for deucrictibant immediate-release capsules and deucrictibant extended-release tablets, which are in late-stage global clinical trials; the outcome of regulatory approvals, including the outcome of our NDA and MAA for the on-demand treatment of acute attacks of HAE; our ability to replicate the efficacy and safety demonstrated in the RAPIDe-1, RAPIDe-2, RAPIDe-3, CHAPTER-1, and CHAPTER-3 Phase 2 and Phase 3 studies in ongoing and future nonclinical studies and clinical trials, such as CREAATE; risks arising from epidemic diseases, which may adversely impact our business, nonclinical studies, and clinical trials; our ability to potentially use deucrictibant for alternative purposes, for example to treat C1-INH deficiency (AAE-C1INH); the value of our ordinary shares; the timing, costs and other limitations involved in obtaining regulatory approval for our product candidates, or any other product candidate that we may develop in the future; our ability to establish commercial capabilities or enter into agreements with third parties to market, sell, and distribute our product candidates; our ability to compete in the pharmaceutical industry, including with respect to existing therapies, emerging potentially competitive therapies and with competitive generic products; our ability to market, commercialize and achieve market acceptance for our product candidates; our ability to produce sufficient amounts of drug product candidates for commercialization; our ability to raise capital when needed and on acceptable terms; regulatory developments in the United States, the European Union and other jurisdictions; our ability to protect our intellectual property and know-how and operate our business without infringing the intellectual property rights or regulatory exclusivity of others; our ability to manage negative consequences from changes in applicable laws and regulations, including tax laws (including the Biosecure Act), our ability to maintain an effective system of internal control over financial reporting; changes and uncertainty in general market conditions; disruptions at the FDA and other agencies; changes and uncertainty in general market, political and economic conditions, including as a result of inflation and geopolitical conflicts; changes in regulations and customs, tariffs and trade barriers; and the other factors described under the headings “Cautionary Statement Regarding Forward-Looking Statements” and “Item 3. Key Information—D. Risk Factors” in our Annual Report on Form 20-F and other periodic filings with the U.S. Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. While Pharvaris may elect to update such forward-looking statements at some point in the future, Pharvaris disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Pharvaris’ views as of any date subsequent to the date of this press release.

CONTACT: Contact
Maggie Beller
Vice President, Head of Corporate and Investor Communications
maggie.beller@pharvaris.com

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Pollen Street Group Limited
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Joint Broker to Pollen Street Group Limited
(d)        Date dealing undertaken:	02nd October 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchases	879	906	904
Ordinary shares	Sales	5000	911	900

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION
        
(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	05th October 2026
Contact name:	Abhishek Gawde
Telephone number:	+91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	SThree Plc
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Joint Broker to SThree Plc
(d)        Date dealing undertaken:	02nd October 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchase	5,000	300	300
Ordinary shares	Sales	105	300.25	300

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	05th October 2026
Contact name:	Abhishek Gawde
Telephone number:	+91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

To Nasdaq Copenhagen A/S                        5 October 2026
                                                                     Announcement no. 85/2026
                                                                     Inside information

Preliminary data on early redemptions (prepayments)

Pursuant to S. 24 of the Capital Markets Act, we hereby publish preliminary data on early redemptions (prepayments) in bonds issued by Jyske Realkredit. Please find the data in the attached file.

The information will also be available on Jyske Realkredit’s web site at jyskerealkredit.com.

For further information about format of data and content of the file we refer to the web site of Nasdaq at www.nasdaqomxnordic.com.

Questions may be addressed to Christian Bech-Ravn, Head of Investor Relations, tel. (+45) 89 89 92 25.

Yours sincerely

Jyske Realkredit

Please observe that the Danish version of this announcement prevails

www.jyskerealkredit.com

Attachment

• 85- ekstraordindfrielse_opgorelsesdato_2026-10-02_oprettet_2026-10-05T08-01-03

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Tribal Group Plc
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Advisor and Joint Broker to Tribal Group Plc
(d)        Date dealing undertaken:	02nd October 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Sales	45	101.5	101.5

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	05th October 2026
Contact name:	Abhishek Gawde
Telephone number:	+91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

SFL Corporation Ltd. (NYSE: SFL) (“SFL” or the “Company”) today announced that it has agreed to build two 93,000 cbm Very Large Ammonia Carriers. The vessels will be able to carry a wide range of petrochemical gases, and will have dual-fuel propulsion and the latest technology for fuel efficiency and cargo intake optimization. Delivery is scheduled from the second quarter of 2028 and the aggregate yard construction cost is expected to be approximately $216 million.

Concurrently, the Company has agreed long term time charters to an oil major, adding a minimum of approximately $162 million to its fixed rate charter backlog. The duration of the initial charter period will be determined within the next six months, and the backlog may increase at that point. The charterer will also have options to extend the time charters by up to 4 years.

Ole B. Hjertaker, CEO of SFL Management AS, said in a comment:

«The gas carrier project marks another accretive milestone investment for SFL, adding assets in a new segment. The charterer is a European based investment grade oil major, underlining SFL’s standing as a high-quality provider of maritime logistics assets. Including acquisitions and charter extensions announced so far this year, we have added more than $1.3 billion to our fixed rate charter backlog in 2026.»

October 5, 2026

The Board of Directors
SFL Corporation Ltd.
Hamilton, Bermuda

Investor and Analyst Contacts:
Espen Nilsen Gjøsund, Vice President – Investor Relations, +47 47 50 05 00

André Reppen, Chief Treasurer & Senior Vice President, +47 23 11 40 55

Aksel Olesen, Chief Financial Officer, +47 23 11 40 36

Media Contact:
Ole B. Hjertaker, Chief Executive Officer, SFL Management AS
+47 23 11 40 11

About SFL

SFL has a unique track record in the maritime industry and has paid dividends every quarter since its initial listing on the New York Stock Exchange in 2004. The Company’s fleet of vessels is comprised of tanker vessels, bulkers, container vessels, car carriers and offshore drilling rigs. SFL’s long term distribution capacity is supported by a portfolio of long term charters and significant growth in the asset base over time. More information can be found on the Company’s website: www.sflcorp.com.

Cautionary Statement Regarding Forward Looking Statements

This press release may contain forward looking statements. These statements are based upon various assumptions, many of which are based, in turn, upon further assumptions, including SFL management’s examination of historical operating trends, data contained in the Company’s records and other data available from third parties. Although SFL believes that these assumptions were reasonable when made, because assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond its control, SFL cannot give assurance that it will achieve or accomplish these expectations, beliefs or intentions.

Important factors that, in the Company’s view, could cause actual results to differ materially from those discussed in the forward looking statements include the strength of world economies, fluctuations in currencies and interest rates, general market conditions in the seaborne transportation industry, which is cyclical and volatile, including fluctuations in charter hire rates and vessel values, changes in demand in the markets in which the Company operates, including shifts in consumer demand from oil towards other energy sources or changes to trade patterns for refined oil products, changes in market demand in countries which import commodities and finished goods and changes in the amount and location of the production of those commodities and finished goods, technological innovation in the sectors in which we operate and quality and efficiency requirements from customers, increased inspection procedures and more restrictive import and export controls, changes in the Company’s operating expenses, including bunker prices, dry-docking and insurance costs, performance of the Company’s charterers and other counterparties with whom the Company deals, the impact of any restructuring of the counterparties with whom the Company deals, and timely delivery of vessels under construction within the contracted price, governmental laws and regulations, including environmental regulations, that add to our costs or the costs of our customers, potential liability from pending or future litigation, potential disruption of shipping routes due to accidents, political instability, terrorist attacks, piracy or international hostilities, and the impact on the demand for commercial seaborne transportation and the condition of the financial markets, and other important factors described from time to time in the reports filed by the Company with the United States Securities and Exchange Commission. SFL disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

DURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it will release its third quarter 2026 financial results before the market opens on Thursday, October 29, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results.

To participate in the conference call, participants should pre-register via the call registration link. All registrants will receive dial-in details and a unique PIN providing access to the live call. To avoid potential delays, participants are encouraged to join at least 10 minutes prior to the start of the call.

The live webcast can be accessed at investors.fortrea.com. A replay will be available in the Events and Presentations section of the site following the conclusion of the call.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn, X and Bluesky.

Fortrea Contacts:

Tracy Krumme (Investors) – 984-385-6707, Tracy.Krumme@fortrea.com
Sue Zaranek (Media) – 919-943-5422, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com

Ramp Up on Track for Start of Commercial Production by End 2026

KELLOGG, Idaho, Oct. 05, 2026 (GLOBE NEWSWIRE) — Bunker Hill Mining Corp. (“Bunker Hill” or the “Company”) (TSX: BNKR | OTCQB: BHLL) is pleased to report that having successfully completed the 14,300ft, 39-hole  underground campaign at the Cate-8 Vein, it has now started a 3,200ft surface drilling program at the recently acquired Page property in the Silver Valley, three miles away from Bunker Hill’s processing facility.

“As our operations team continue the steady ramp up to commercial production by the end of 2026, it is exciting to report that, following the positive results of their Cate-8 underground drilling campaign, the exploration team has hit, with their first drill hole, another area of highly prospective Galena-Siderite and Sphalerite mineralization near surface at our recently acquired Page property,” said Sam Ash, President and Chief Executive Officer of Bunker Hill. “This further supports the potential to be unlocked by the Bunker team in our 6,284-hectare portion of the prolific Silver Valley.”

EXPLORATION UPDATE

Bunker Hill’s current exploration program is focused on identifying targets that could expand mineral resources in a cost-effective manner, with priority given to targets near surface and near existing mine infrastructure across its recently expanded property. These targets are identified primarily by analysis of historical mining and exploration data collected over 100 years, which Bunker Hill is re-interpreting using modern methods, including the use of AI tools where appropriate. Historical data has not been fully verified by a qualified person, and there is no certainty that exploration of these targets will result in the delineation of additional mineral resources.

• The Cate-8 Vein: the data collected from 14,300ft of drilling over 39 shallow holes and samples collected from development that cut the mineralization are being assayed, collated and processed to support inclusion within an updated resource statement expected to be issued by end of Q4 2026.

  Subject to further analysis and given its proximity to existing mine development, it is expected that any Cate-8 mineral resources will be included within the 2027 mine plan to be issued within the Company’s production guidance expected to be released at the end of Q4 2026.

• Initial Page Exploration: following up on historical surface drilling results achieved in 2025 by the previous owners of the property in the vicinity of the Page mine, the Bunker Hill exploration team has started 3,200ft (975m) of shallow drilling from 10 holes from surface. This is expected to take six weeks to complete. This site is accessed by paved and forest roads and is the same distance from the Bunker Hill processing plant as the Russell Portal in Wardner.

  Based on visual assessment, the initial results from the first hole indicate 15ft of continuous Galena-Siderite and Sphalerite mineralization at a depth from surface of approximately 200ft. Visual estimates of mineralization are not a substitute for laboratory assays and should not be relied upon as an indication of grade or the extent of mineralization, which can only be determined through assay results to be completed as the Page exploration campaign progresses.

Fig 1: Location of Page Drilling Site in relation to the operating processing plant at Kellogg.

RAMP UP TO COMMERCIAL PRODUCTION

Active mining operations are being conducted within the upper area of the Bunker Hill Mine, including development being cut through the recently discovered Cate-8 vein. Ore is being transported to the operating processing plant in line with the ramp-up schedule, and the commissioning of the processing plant and ramp up of mining are progressing in line with the Company’s target of achieving commercial production by the end of 2026. Safety remains a priority, with the Company recording 553 consecutive days without a reportable incident.

During September, Bunker Hill fully commissioned the paste plant and on-boarded the fourth mining crew, enabling the start of continuous 1800 tonnes per day (“tpd”) underground mining operations. Having used low-grade stockpiles for the early phases of plant commissioning, the underground team is now feeding Run of Mine Ore into the plant at targeted head grade, from two active stopes on the 5 and 8-2 levels. Operating performance, including costs, remains in line with pre-production estimates.

To stretch the team’s performance and mirror commissioning best practice, the Company has revised its definition of commercial production, previously defined as achieving at least 65% of 1800 tpd “nameplate” throughput capacity only, to include metal recovery targets as well. From now, the operations required by end of Q4 2026 to achieve commercial production are: throughput of at least 65% of nameplate capacity, and zinc/lead/silver recovery of at least 70%, for 60 days.

2027 MINE PLANNING UPDATE

Subject to further analysis, including the results of the updated resource statement and further technical and economic evaluation, the mine planners are preparing to incorporate Cate-8 mineral resources into the 2027-2030 mine plan. The team is also investigating ways to overcome the existing single access/single egress constraint on mine haulage, which currently consists of the Russel Portal in Wardner, located 3.5 miles from the processing plant.

To that end, studies are ongoing now to evaluation the potential construction of a second 6,000ft portal, located just over a mile from the processing plant with direct access to the 10 Level to enable a more efficient ore and waste haulage system. The Company is also studying modifications to the processing plant to increase capacity to 2500tpd. In support of this, the Company recently acquired 60 acres of land adjacent to and uphill from the processing facility for potential use as a dry-stack tailings facility.

The Company currently expects to issue its production guidance for 2027 by the end of Q4 2026.

QUALIFIED PERSON

Sam Bourque (AIPG CPG #11775), Chief Geologist of Bunker Hill, is the Company’s designated Qualified Person for this news release within the meaning of National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Mr. Bourque has reviewed and approved the technical information contained herein.

ABOUT BUNKER HILL MINING CORP.

Bunker Hill Mining Corp. is a U.S.-based exploration and development company focused on the restart of its flagship asset — the historic Bunker Hill Mine in northern Idaho’s prolific Silver Valley. This renowned silver, zinc, and lead deposit is being advanced using modern exploration techniques and responsible development practices to unlock its full potential.

The Company’s strategy is centered on efficiently revitalizing this high-quality asset to deliver long-term value, while upholding strong environmental and operational standards. Bunker Hill is committed to maximizing shareholder returns through the disciplined redevelopment of one of North America’s most storied mining operations.

Additional information is available at www.bunkerhillmining.com and on SEDAR+ and EDGAR.

On behalf of Bunker Hill Mining Corp.
Sam Ash
President and Chief Executive Officer

For additional information, please contact:
Bunker Hill Investor Relations
T: 604.842.1384
E: ir@bunkerhillmining.com

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this news release are forward-looking and involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, as well as within the meaning of the phrase “forward-looking information” in the Canadian Securities Administrators’ National Instrument 51-102 – Continuous Disclosure Obligations (collectively, “forward-looking statements”). Forward-looking statements are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, “plan” or variations of such words and phrases.

Forward-looking statements in this news release include, but are not limited to, statements regarding: additional zones of mineralization; the focus of Bunker Hill’s exploration program; initial and future drill, exploration and testing programs at the Page property; geological interpretations and resource calculations; expectations regarding the incorporation of any Cate-8 mineral resources into short-term mine plans; expectations regarding an updated mineral resource statement and the anticipated timing thereof; the anticipated timing of the issuance of 2027 production guidance; the ramp-up to commercial production at the Bunker Hill Mine; the installation of an additional portal to access the Bunker Hill Mine and improvements at the processing plant to increase throughput capacity; and the Company’s general objectives, goals or future plans, and any similar statements. Forward-looking statements reflect material expectations and assumptions, including, without limitation, expectations and assumptions relating to:  sufficiency of project financing for the ramp up of commercial production of the Bunker Hill Mine on acceptable terms or at all; the future price of metals; and the stability of the financial and capital markets. Factors that could cause actual results to differ materially from such forward-looking statements include, but are not limited to, those risks and uncertainties identified in public filings made by Bunker Hill with the U.S. Securities and Exchange Commission (the “SEC”) and with applicable Canadian securities regulatory authorities, including its latest annual report on Form 10-K as filed with the SEC on March 6, 2026, and the following: the Company’s inability to raise additional capital for project activities, including through equity financings, concentrate offtake financings or otherwise; capital market conditions;  failure to identify mineral resources; failure to convert estimated mineral resources to reserves; the preliminary nature of metallurgical test results; the Company’s ability to ramp up the Bunker Hill Mine to commercial production and the risks of not basing a production decision on a feasibility study of mineral reserves demonstrating economic and technical viability . Although the Company believes that the assumptions and factors used in preparing the forward-looking statements in this news release are reasonable, undue reliance should not be placed on such statements or information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Readers are cautioned that the foregoing risks and uncertainties are not exhaustive. Additional information on these and other risk factors that could affect the Company’s operations or financial results are included in the Company’s annual report and may be accessed through the SEDAR+ website (www.sedarplus.ca) or through EDGAR on the SEC website (www.sec.gov).

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/53835771-f8ae-474a-9b6d-7a0c3ef416a1

HOUSTON and LONDON, Oct. 05, 2026 (GLOBE NEWSWIRE) — LyondellBasell (NYSE: LYB), a leader in the global chemical industry, will announce its third-quarter 2026 financial results before the U.S. market opens Friday, Oct. 30, followed by a webcast and teleconference to discuss the results at 11 a.m. EDT.

Teleconference and webcast details
Friday, Oct. 30, 2026
11 a.m. EDT
Hosted by David Dennison, head of investor relations
Access the webcast 10 to 15 minutes prior to the start of the call at www.lyb.com/earnings.

Toll-free teleconference dial-in numbers
Participant/Guest toll-free: 877-407-8029
Participant/Guest toll: 201-689-8029
Participant/Guest: CallMe link

Presentation slides
Presentation slides will be available at the time of the teleconference and afterward at www.lyb.com/earnings.

Replay information
A replay of the call will be available from 1 p.m. EDT Oct. 30 until Nov. 30, 2026. The replay dial-in numbers are:
Toll-Free: 877-660-6853
Toll: 201-612-7415
Access ID: 13746219

About LyondellBasell 
We are LyondellBasell (NYSE: LYB) – a leader in the global chemical industry creating solutions for everyday sustainable living. Through advanced technology and focused investments, we are enabling a circular and low carbon economy. Across all we do, we aim to unlock value for our customers, investors and society. As one of the world’s largest producers of polymers and a leader in polyolefin technologies, we develop, manufacture and market high-quality and innovative products for applications ranging from sustainable transportation and food safety to clean water and quality healthcare. For more information, please visit www.lyondellbasell.com or follow @LyondellBasell on LinkedIn.

CONTACT: Barrie Lee
LyondellBasell
713-309-7575
sarah.allen@lyondellbasell.com